Company Overview and News
Stocks in Asia weakened Friday following President Donald Trump’s sudden cancellation of a June summit with North Korean leader Kim Jong Un. Still, investors’ worries about the scrapped meeting were softened by expectations that the two countries could continue their dialogue. South Korea’s Kospi trimmed an early 0.5% loss to fall just 0.1%, while major benchmarks in Hong Kong, mainland China and Japan were all down less than 0.
Hong Kong-listed stock loses more than 11 per cent of its value in first four minutes of trading
Shares in Hong Kong-listed branded luggage maker Samsonite International plummeted by more than 11 per cent in early trading in Hong Kong on Thursday, after being accused of “questionable accounting practises” and “poor corporate governance”, in a report by newly formed activist short-seller, Blue Orca Capital.
The buying surged for the third straight week while the selling among directors remained high based on filings during the three-day trading week from April 3 to 6. Buyers outweighed sellers with 56 companies that recorded 241 purchases worth HK$203 million (US$25.89 million) versus 12 firms with 32 disposals worth HK$50 million
SHANGHAI: President Donald Trump’s move to slap tariffs on at least $50 billion in Chinese imports is likely to be bad news for many of China’s exporters – as well as Americans who like wearing Victoria’s Secret bras, Guess jeans or Nike sneakers.
Shanghai: US President Donald Trump’s move to slap tariffs on at least $50 billion in Chinese imports is likely to be bad news for many of China’s exporters—as well as Americans who like wearing Victoria’s Secret bras, Guess jeans or Nike sneakers.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The logo of Tumi is seen in a shop in downtown Rome, March 4, 2018. — Reuters picHONG KONG, March 19 — Samsonite International SA, the world’s biggest luggage maker, has its eyes on adding a handbag brand and is open to a deal that could rival its US$1.8 billion purchase of Tumi, according to Chairman Timothy Charles Parker.
Hello, and welcome to the Samsonite International 2017 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. And please note, this event is being recorded.
Sydney/Hong Kong: Some of China’s biggest manufacturers that supply US multinationals from Walmart Inc. to Nike Inc. find themselves in President Donald Trump’s cross hairs as his administration discusses new import tariffs.
An employee works at a garment factory in Quanzhou county, Guangxi Ethnic Zhuang autonomous region in China July 15, 2013. — Reuters picWASHINGTON, March 7 — President Donald Trump’s latest threat to impose tariffs on a range of imports from China risks ensnaring some of the country’s most successful manufacturers that supply US multinationals from Walmart Inc to Nike Inc.
The buying fell for the first time in the past five weeks while the selling among directors surged for the second straight week based on filings on the Hong Kong stock exchange from January 8 to 12. A total of 47 companies recorded 200 purchases worth HK$129 million (US$16.5 million) versus 28 firms with 117 disposals worth HK$328 million. The buy figures were down from the previous week’s four-day total of 48 companies, 207 purchases and HK$173 million.
Women travellers could account for 25 per cent of total sales by 2021, and up to 50 per cent in the next 10 to 15 years, Samsonite’s CEO said.
Beijing/Shanghai: The great Chinese environmental cleanup, now in full swing, is shifting the corporate landscape in unexpected ways and even stoking inflationary pressure that may soon be felt in supply chains worldwide.
Cost of meeting environmental regulations is increasing companies’ costs and leading some firms to consider moving production abroad, according to analysts
13h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
13h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...